BUSINESS
Anatomy of Mutual Reliance - Diovan Papers and Company Part 2: Explanations to the World Urged
“This finding seems strange to me.” It was a brief correspondence published in April 2012 in The Lancet, one of the world’s most prestigious medical journals, that unleashed a scandal surrounding large-scale domestic clinical studies on Diovan (valsartan), Novartis Pharma’s…
To read the full story
Related Article
BUSINESS
- Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
- Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
- FDA Rejects Regenxbio/Nippon Shinyaku’s MPS II Gene Therapy
February 12, 2026
- Celltrion to Launch Japan’s First Actemra Biosimilar in Late April
February 12, 2026
- MFN Policy Could Affect Business Outside US: Kyowa Kirin CEO
February 12, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





